Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2380)	10/3/2008 12:33:19 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

YMI is trying to get back to the $0.50 level <g> As previously mentioned, The stock remains on the DT coming from its March 2006 H at $6.50 It is trading around 0.25xBV & below its cash/shr, around $0.90 <g> YMI has been consistently trimming its losses for the last 4Qs and revenues also improved in the 4thQ (June) In Aug they reported preliminary results obtained from its open-label, PII of YMB1000-01 (nimotuzumab) in patients with irinotecan-refractory, metastatic colorectal Cas which showed a favorable overall survival of 9.3 months and disease control rate of 50% together with very good safety profile. They said that they were planning to continue development of nimotuzumab for patients with colorectal Cas. Nimotuzumab is also being evaluated in two PIIIs as a first-line treatment for pediatric pontine glioma and adult glioma, in a PII/III as a treatment for pancreatic cancer, it has been approved for marketing in eight countries and is currently under review for marketing approval by EMEA This week they announced that two of its licensees for nimotuzumab, in Japan and Korea, advised that they started the enrollment in an 80-patient PII trial of nimotuzumab plus irinotecan compared to irinotecan alone in patients with advanced or recurrent gastric Ca who are refractory to 5-FU. I am not holding any YMI shrs., but in spite of the present market conditions, will probably start a position, since a move from $0.50 to the resistance at $0.75 wil be a 50% gain & with YMI's BV and cash, it seems the R/R at this level isn't bad.<g> bigcharts.marketwatch.com Bernard